Patent · US Active

Antibody drug conjugates (ADC) that bind to FLT3 proteins

US10751422B2 · kind B2 · utility

1Cited by

1References

13Claims

0Family size

Assignee

Latency, LLC · US

Inventors

Nandini Rudra-Ganguly · Santa Monica, US
Christine Lowe · San Fernando, US
Faisal Hayat Malik · Cerritos, US
Sung-Ju Moon · New Providence, US
Josh SNYDER · Santa Monica, US
Hector Avina · Los Angeles, US
Cyrus Virata · Mission Hills, US
Linnette Capo · West Hollywood, US
Gao Liu · Mountain View, US

Key dates

Filing date	Mar 9, 2016
Grant date	Aug 25, 2020
Priority date	—
Expiry date	Mar 9, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/732
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.